TTP: toward targeted therapy and precision medicine. P. Coppo, A. Cuker, JN. George. Res Pract Thromb Haemost 2018;3:26-37.

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Jestin M, Benhamou Y, Schelpe AS, Roose E, Provôt F, Galicier L, Hié M, Presne C, Poullin P, Wynckel A, Saheb S, Deligny C, Servais A, Girault S, Delmas Y, Kanouni T, Lautrette A, Chauveau D, Mousson C, Perez P, Halimi JM, Charvet-Rumpler A, Hamidou M, Cathébras P, Vanhoorelbeke K, Veyradier A, Coppo P; French Thrombotic Microangiopathies Reference Center. Blood 2018;132:2143-53.

ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshaw-Schulman Syndrome. Joly BS, Boisseau P, Roose E, Stepanian A, Biebuyck N, Hogan J, Provot F, Delmas Y, Garrec C, Vanhoorelbeke K, Coppo P, Veyradier A; French Reference Center for Thrombotic Microangiopathies. Thrombosis Haemostasis 2018;118:1902-17.

Pediatric thrombotic thrombocytopenic purpura. Joly BS, Coppo P, Veyradier A. Eur J Haematol. 2018;101:425-34.

Understanding thrombotic microangiopathies in children. Joly BS, Zheng XL, Veyradier A. Intensive Care Med. 2018;44:1536.

Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers. Hrdinová J, D'Angelo S, Graça NAG, Ercig B, Vanhoorelbeke K, Veyradier A, Voorberg J, Coppo P. Haematologica 2018;103:1099-109.

An open conformation of ADAMTS-13 is a hallmark of acute acquired TTP. Roose E, Schelpe AS, Joly BS, Peetermans M, Verhamme P, Voorberg J, Greinacher A, Deckmyn H, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K. J Thromb Haemost. 2018;16:378-88.